Zhiming Li

3.4k total citations
147 papers, 1.9k citations indexed

About

Zhiming Li is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Zhiming Li has authored 147 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Pathology and Forensic Medicine, 74 papers in Oncology and 36 papers in Immunology. Recurrent topics in Zhiming Li's work include Lymphoma Diagnosis and Treatment (86 papers), Viral-associated cancers and disorders (35 papers) and CNS Lymphoma Diagnosis and Treatment (22 papers). Zhiming Li is often cited by papers focused on Lymphoma Diagnosis and Treatment (86 papers), Viral-associated cancers and disorders (35 papers) and CNS Lymphoma Diagnosis and Treatment (22 papers). Zhiming Li collaborates with scholars based in China, United States and Switzerland. Zhiming Li's co-authors include Yi Xia, Wen-Qi Jiang, Yu Wang, Peng Sun, Panpan Liu, Hui-Qiang Huang, Jia-Jia Huang, Man Nie, Tong-Yu Lin and Wenqi Jiang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Zhiming Li

132 papers receiving 1.8k citations

Peers

Zhiming Li

PFM

ONCOL

IMMUN

NEURO

Alexander Deutsch Austria

Sung‐Hoon Jung South Korea

Hyeoung‐Joon Kim South Korea

Paloma Martín Spain

Theodoros P. Vassilakopoulos Greece

Ling Xue China

Sotirios G. Papageorgiou Greece

Lukas Weiß Austria

Josef Birkmann Germany

Shintaro Hirata Japan

Alexander Deutsch Austria

Zhiming Li

519 ×0.6

PFM

530 ×0.7

ONCOL

299 ×0.5

IMMUN

530 ×1.5

128 ×0.6

NEURO

Citations per year, relative to Zhiming Li Zhiming Li (= 1×) peers Alexander Deutsch

Countries citing papers authored by Zhiming Li

Since Specialization

Citations

This map shows the geographic impact of Zhiming Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhiming Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhiming Li more than expected).

Fields of papers citing papers by Zhiming Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhiming Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhiming Li. The network helps show where Zhiming Li may publish in the future.

Co-authorship network of co-authors of Zhiming Li

This figure shows the co-authorship network connecting the top 25 collaborators of Zhiming Li. A scholar is included among the top collaborators of Zhiming Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhiming Li. Zhiming Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gao, Yan, et al.. (2025). High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study. Blood Cancer Discovery. 6(3). 191–202. 3 indexed citations

Cao, Fei, Ke Jiang, Jian Zhou, et al.. (2025). Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial. Clinical Cancer Research. 31(18). 3876–3885.

Sun, Xiaoqing, Caiqin Wang, Jing Li, et al.. (2024). Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance. Journal of Advanced Research. 73. 631–644. 3 indexed citations

Zhang, Weilin, Tao Zhang, Xiaoqing Chen, et al.. (2024). 1414P Iparomlimab and tuvonralimab (QL1706) with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: An open-label phase II study. Annals of Oncology. 35. S883–S883. 1 indexed citations

Wang, Xinqi, et al.. (2024). Interactions between Brassinosteroids and Strigolactones in Alleviating Salt Stress in Maize. International Journal of Molecular Sciences. 25(19). 10505–10505. 5 indexed citations

Li, Zhiming, Xiang Li, Li Su, et al.. (2024). Preclinical evaluation and phase 1 study of the PI3Kα/δ inhibitor TQ‐B3525 in Chinese patients with advanced cancers. Cancer. 130(21). 3686–3698. 2 indexed citations

Yang, Jianliang, Yongping Song, Keshu Zhou, et al.. (2024). Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7060–7060. 2 indexed citations

Li, Zhiming, Zijie Wang, Lei Zhu, et al.. (2024). Genetically proxied appendicular lean mass and stroke risk: A two-step mendelian randomization study. Journal of Stroke and Cerebrovascular Diseases. 33(10). 107915–107915. 1 indexed citations

Yang, Jianliang, Keshu Zhou, Zhiming Li, et al.. (2024). Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study. Journal of Hematology & Oncology. 17(1). 123–123. 3 indexed citations

10.

Yan, Jun, Enhui Wang, Jun Xiao, et al.. (2023). Black carp RNF5 inhibits STING/IFN signaling through promoting K48-linked ubiquitination and degradation of STING. Developmental & Comparative Immunology. 145. 104712–104712. 6 indexed citations

11.

Sun, Peng, Yajun Li, Cong Li, et al.. (2023). A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first‐line therapy in patients with newly diagnosed, stage I–II extranodal natural‐killer/T‐cell lymphoma. American Journal of Hematology. 98(7). 1043–1051. 9 indexed citations

12.

Li, Zhiming, et al.. (2023). Modelling and analysis of the HIV/AIDS epidemic with fast and slow asymptomatic infections in China from 2008 to 2021. Mathematical Biosciences & Engineering. 20(12). 20770–20794. 1 indexed citations

13.

Li, Jian, Jing Han, Yu Wang, et al.. (2020). Core Needle Biopsy Targeting the Viable Area of Deep-Sited Dominant Lesion Verified by Color Doppler and/or Contrast-Enhanced Ultrasound Contribute to the Actionable Diagnosis of the Patients Suspicious of Lymphoma. Frontiers in Oncology. 10. 500153–500153. 5 indexed citations

14.

Nie, Man, Linbin Yang, Xiwen Bi, et al.. (2018). Neutrophil Extracellular Traps Induced by IL8 Promote Diffuse Large B-cell Lymphoma Progression via the TLR9 Signaling. Clinical Cancer Research. 25(6). 1867–1879. 206 indexed citations

15.

Liu, Panpan, Kefeng Wang, Jietian Jin, et al.. (2018). Role of radiation therapy in primary breast diffuse large B‐cell lymphoma in the Rituximab era: a SEER database analysis. Cancer Medicine. 7(5). 1845–1851. 12 indexed citations

16.

Gao, Yan, Huiqiang Huang, Pengfei Li, et al.. (2017). Chidamide ,Oral Subtype-Selective Histone Deacetylase Inhibitor (HDACI) Monotherapy Was Effective on the Patients with Relapsed or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma. Blood. 130. 2797–2797. 7 indexed citations

17.

Chen, Jun, Hong Wang, & Zhiming Li. (2017). Association between Polymorphisms of X-Ray Repair Cross Complementing Group 1 Gene and Pancreatic Cancer Risk: a Systematic Review with Meta-Analysis. Pathology & Oncology Research. 25(3). 897–904. 3 indexed citations

18.

Liu, Panpan, Yi Xia, Xi-Wen Bi, et al.. (2016). Racial patterns of patients with primary mediastinal large B-cell lymphoma. Medicine. 95(27). e4054–e4054. 33 indexed citations

19.

Li, Zhiming, Li Zhong, Long Gu, et al.. (2016). Association study of TREM2 polymorphism rs75932628 with leucoaraiosis or Parkinson's disease in the Han Chinese population. BMJ Open. 6(1). e009499–e009499. 12 indexed citations

20.

Li, Zhiming, Hui-Qiang Huang, Zhong-Jun Xia, et al.. (2013). Prognostic Value of Interim and Posttherapy ¹⁸F-FDG PET/CT in Patients with Mature T-Cell and Natural Killer Cell Lymphomas. Journal of Nuclear Medicine. 54(4). 507–515. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact